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First, we found that the incidence of atypical 
femur fracture was unrelated to BMD and only 
weakly related to age. Second, when we per-
formed a subgroup analysis in the Kaiser Perma-
nente cohort that was limited to women who 
were older than 65 years of age and who had a 
BMD T-score of less than −2.5, we found an in-
cidence of atypical femur fracture similar to the 
incidence in the overall cohort (unpublished 
data). The correspondents question whether we 
overestimated the fracture benefit of 5 to 10 years 
of alendronate, since the FLEX trial1 and obser-
vational data2 showed no increase in the risk of 
clinical fracture after alendronate was discontin-
ued after 5 years. However, studies involving 
patients with 5 years of previous treatment are 
not relevant, since our estimate of the fractures 
that were prevented with alendronate was based 
on a comparison of women who were never 
treated with those who were continuously treat-
ed. We agree that our findings that show large 
decreases in the risk of atypical femur fracture 
after the discontinuation of alendronate provide 
support for a drug holiday after 5 years, particu-
larly for women at lower risk.
Garton questions whether an underestima-
tion of the incidence of atypical femur fracture 
biases the ratio of such fractures to fragility 
fractures. However, we think that our adjudica-
tion, starting with all femoral-shaft or subtro-
chanteric fractures, identified virtually all com-
plete unilateral and bilateral atypical femur 
fractures. However, incomplete fractures would 
not have been included unless they had been 
prophylactically repaired. We agree that accumu-
lating microdamage is part of the pathophysiol-
ogy of atypical femur fracture, but its effect on 
only a small minority of patients remains unex-
plained.3 Regarding the consequences of atypi-
cal femur fracture as compared with hip frac-
ture, several studies have suggested similar 
mortality4 after either type of fracture, although 
surgical repair of atypical femur fractures can be 
more challenging.3
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JAK Inhibition in the Aicardi–Goutières Syndrome
To the Editor: Some reports,1-3 including that of 
Vanderver et al. (Sept. 3 issue),4 have indicated 
the potential of Janus kinase 1 (JAK1) blockade 
in the treatment of type I interferonopathies. We 
describe here the onset of the Aicardi–Goutières 
syndrome, despite the use of ruxolitinib for 10 
months, in a patient who had been presymp-
tomatic.
A 4-month-old male infant with biallelic 
RNASEH2B mutations was identified after an 
older sibling received a diagnosis of the Aicardi–
Goutières syndrome. The infant’s development 
had been normal until that time, but he had 
markers that were suggestive of interferon-sig-
naling activation (Fig. S1 in the Supplementary 
Appendix, available with the full text of this let-
ter at NEJM.org). Therefore, when he was 5 months 
of age, we initiated therapy with ruxolitinib at a 
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dose of 5 mg twice daily. When he was 11 
months of age, the dose was increased to 7.5 mg 
twice daily (1 mg per kilogram of body weight 
per day).
At 12 months of age, the patient’s neurologic 
status remained normal. At 13 months of age, 
he had weekly fevers. Ruxolitinib was discontin-
ued twice, for 3 days on each occasion, in the 
14th month of life. His immunization history 
included the administration of hepatitis A vac-
cine at 13 months of age (see the Supplementary 
Appendix). At 15 months of age, up to which 
time his neurologic status was normal, he had 
an abrupt onset of irritability and neurologic 
deterioration. At 17 months of age, he had spas-
tic–dystonic tetraparesis and was no longer able 
to speak.
We observed that the concentration of ruxoli-
tinib in the patient’s cerebrospinal fluid (CSF) 
was approximately 10% of that in the plasma; 
a similar finding was observed in three other 
patients with the Aicardi–Goutières syndrome 
(Table S1). Better penetration into the central 
nervous system or combination therapy5 might 
have prevented disease manifestation.
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Figure 1 (next page). Interferon-Signaling Gene (ISG) Expression Scores in the Context of Infection and Vaccination 
and Aicardi–Goutières Syndrome Scores in Patients Treated with Baricitinib.
In our study, one patient with homozygous RNASEH2B mutations had elevated ISG scores after influenza vaccination, 
which had been administered hours before the sample was obtained, and during a viral illness with fever (Panel A, 
left graph). Control values (from patients without interferonopathy) are shown in the right graph. In a different co-
hort,1 a patient who had the Aicardi–Goutières syndrome with homozygous SAMHD1 deletions had a decrease in 
ISG scores and improved clinical findings during baricitinib therapy (Panel B, left graph). During the study, the pa-
tient had three infections (a proteus urinary tract infection [UTI], sinusitis, and strep throat), which were treated with 
antibiotic agents and were associated with elevated ISG scores. Control values (from patients without interferonopa-
thy or with CANDLE [chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures] or SAVI 
[stimulator of interferon genes–associated vasculopathy with onset in infancy]) are shown in the right graph. The 
specific methods for assessing the ISG scores shown in Panels A and B varied between the two study cohorts1,2; in 
both cases, higher scores indicate greater interferon signaling. In an additional patient, baricitinib therapy was in-
terrupted owing to concerns with infection (Panel C). Subsequently, neurologic skills, as measured by the Aicardi–
Goutières syndrome scale (on which scores range from 0 to 11, with increased scores indicating discrete milestones 
gained),3 were lost. Evaluation of developmental milestones, assessed according to the Aicardi–Goutières syndrome 
scale, is shown for two sibling pairs in our study (Panel D); shown are scores from before treatment, the baseline 
visit at the initiation of baricitinib treatment, and the last available scores. The older siblings (red) met developmen-
tal milestones while they were receiving baricitinib, and the younger siblings (blue) met age-appropriate develop-
ment milestones as of the last evaluation. Asterisks indicate the initiation of baricitinib therapy.
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The authors and a colleague reply: The 
Aicardi–Goutières syndrome is a disease of per-
sistent interferon dysregulation. Neven et al. 
point to the importance of identifying potential 
disease triggers. Across two separate cohorts of 
patients who had interferonopathies treated with 
baricitinib (from our study and from a study by 
Montealegre Sanchez et al.1), there are examples 
of patients with the Aicardi–Goutières syndrome 
who had scores indicating elevated interferon-
signaling gene (ISG) expression related to envi-
ronmental factors, such as infection and vaccina-
tion (Fig. 1A and 1B).
In addition, early and uninterrupted treat-
ment with JAK inhibitors may be important. In 
one patient in our study, baricitinib therapy was 
interrupted for 2 days because of infection con-
cerns, and the dose was subsequently reduced. 
While baricitinib was not being administered, 
this patient lost neurologic skills, which have 
not been regained despite resumption of the 
dose (Fig. 1C). Two patients in our study had 
younger siblings who had early symptoms — 
one with toe walking, and the other with torti-
collis — and who were treated with baricitinib 
(Fig. 1D). To date, with baricitinib therapy, the 
younger siblings have met age-appropriate mile-
stones without regression. We did not assess 
CSF pharmacokinetics in our study.
The Aicardi–Goutières syndrome is a disease 
of fluctuating interferon dysregulation, which 
can be exacerbated by environmental factors. 
Although there are gaps in knowledge regarding 
dose levels, target engagement, CSF penetration, 
environmental risk factors, and the comparison 
of different JAK inhibitors, our work suggests 
that early identification and consistent treatment 
with JAK inhibitors may positively affect neuro-
logic outcomes in patients with the Aicardi–
Goutières syndrome.
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